Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study | PLOS ONE
Cancers | Free Full-Text | Valproic Acid and Breast Cancer: State of the Art in 2021
MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation - ScienceDirect
Ki-67-Based Breast Cancer Recurrence Data | Food for Breast Cancer
Expression of ER, PR, Her2, and Ki-67 by immunohistochemical staining... | Download Scientific Diagram
Relazione tra anticipazione diagnostica e terapie: confronto fra cancri della mammella in donne sottoposte e non a screening
Scholarly Article or Book Chapter | Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer | ID: h989r975x | Carolina Digital Repository
Medicina | Free Full-Text | Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice
การแบ่งประเภททางโมเลกุลของมะเร็งเต้านม (Molecular classification of breast cancer) | Asian Archives of Pathology
Subtypes of Breast Cancer: Luminal B - StoryMD
Cyclin A2 and Ki-67 proliferation markers could be used to identify tumors with poor prognosis in African American women with breast cancer
Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens | Virchows Archiv
PinPointcases - INACTIVE --- Adjuvant systemic treatment of luminal A/B early breast cancer
Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. - Abstract - Europe PMC
![PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a33aa443a365c6282bd5449f8899f125cb99c7a9/3-Table3-1.png "PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar")
PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar
MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation - Modern Pathology
Effect of Ki-67 Expression Levels and Histological Grade on Breast Cancer Early Relapse in Patients with Different Immunohistochemical-based Subtypes | Scientific Reports
MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers | Diagnostic Pathology | Full Text
Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer | Scientific Reports
The expression of ki-67 by subtypes tumor of breast cancer | Download Scientific Diagram
Initial Treatment Decisions | Breast Surgery Specialist Melbourne, VIC
ROC curve to determine the best Ki-67 cut-point to differentiate... | Download Scientific Diagram
JPM | Free Full-Text | Correlation between Androgen Receptor Expression in Luminal B (HER–2 Negative) Breast Cancer and Disease Outcomes
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
![PDF] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/60a5e17db2ebec70ad7ebb9addd7b2a5f3bf9992/6-Figure1-1.png "PDF] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer | Semantic Scholar")